Figure 7.

(a) Schematic “proof of concept” of a patient with colorectal cancer liver metastases with selective tumor uptake of (b) ¹⁷⁷Lu₂O₃-iPSMA/¹⁷⁷Lu₂O₃-iFAP nanoparticles (c) initially captured by the liver reticuloenthotelial system and by tumor metastases due to an enhanced permeability and retention (EPR) effect, but not by healthy hepatocytes of the liver parenchyma; subsequently, retained within tumors by a specific mechanism mediated both by overexpressed receptors on the surface of cancer cells (e.g., PSMA), and by receptors of the tumor microenvironment (e.g., FAP and PSMA).